Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis

CONTEXT: No head-to-head trials have directly compared once-weekly (OW) semaglutide, a human glucagon-like peptide-1 analog, with empagliflozin, a sodium–glucose co-transporter-2 inhibitor, in type 2 diabetes (T2D). OBJECTIVE: We indirectly compared the efficacy of OW semaglutide 1 mg vs once-daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingvay, Ildiko, Capehorn, Matthew S, Catarig, Andrei-Mircea, Johansen, Pierre, Lawson, Jack, Sandberg, Anna, Shaw, Robert, Paine, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549924/
https://www.ncbi.nlm.nih.gov/pubmed/32827435
http://dx.doi.org/10.1210/clinem/dgaa577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549924/
https://www.ncbi.nlm.nih.gov/pubmed/32827435
http://dx.doi.org/10.1210/clinem/dgaa577

Ejemplares similares